
CYCCP
Healthcare · Biotechnology · $9.6M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Sep 30, 2021 | Time not confirmed | 0.00 | -0.54 | — |
| Jun 30, 2021 | Time not confirmed | 0.00 | -0.56 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.50 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -1.34 | — |
| Aug 12, 2020 | After the close | -0.47 | -0.58 | -23.4% |
| May 12, 2020 | After the close | -2.90 | -1.48 | +49.0% |
| Feb 26, 2020 | After the close | -2.70 | -2.80 | -3.7% |
| Nov 13, 2019 | After the close | -3.13 | -2.20 | +29.7% |
| Aug 13, 2019 | After the close | -3.13 | -2.20 | +29.7% |
| May 14, 2019 | After the close | -4.10 | -2.80 | +31.7% |
| Mar 27, 2019 | After the close | -3.47 | -3.40 | +2.0% |
| Nov 12, 2018 | After the close | -3.40 | -3.60 | -5.9% |
| Aug 9, 2018 | After the close | -2.40 | -3.20 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
| -33.3% |
| May 14, 2018 | After the close | -2.60 | -2.40 | +7.7% |
| Mar 28, 2018 | After the close | 0.00 | -2.33 | — |